Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(66), 2022

DOI: 10.1128/aac.01543-21

Links

Tools

Export citation

Search in Google Scholar

Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells

Journal article published in 2022 by Nilima Dinesh Kumar, Bram M. ter Ellen, Ellen M. Bouma, Berit Troost, Denise P. I. van de Pol, Heidi H. van der Ende-Metselaar, Djoke van Gosliga, Leonie Apperloo, Orestes A. Carpaij, Maarten van den Berge ORCID, Martijn C. Nawijn ORCID, Ymkje Stienstra, Izabela A. Rodenhuis-Zybert ORCID, Jolanda M. Smit ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Antiviral therapies are urgently needed to treat and limit the development of severe COVID-19 disease. Ivermectin, a broad-spectrum anti-parasitic agent, has been shown to have anti-SARS-CoV-2 activity in Vero cells at a concentration of 5 μM.